2023 World Conference on Lung Cancer (Posters)-P2.03. Effectiveness and Safety of Combining Bevacizumab and Fractionated Stereotactic Radiotherapy for Brain Metastases in NSCLC Patients

P2.03. Effectiveness and Safety of Combining Bevacizumab and Fractionated Stereotactic Radiotherapy for Brain Metastases in NSCLC Patients - PDF(Slides)

Back to course

Pdf Summary

A prospective phase II study investigated the efficacy and safety of combining bevacizumab and fractionated stereotactic radiotherapy (FSRT) for brain metastases in patients with non-small cell lung cancer (NSCLC). The study aimed to improve intra-cranial disease control by exploring the synergy between radiotherapy and angiogenesis inhibitors. NSCLC patients with brain metastases were recruited and assigned to receive FSRT with bevacizumab. The primary endpoint was intra-cranial progression-free survival (IPFS), and secondary endpoints included overall survival (OS), progression-free survival (PFS), quality of life (QOL), and toxicities.<br /><br />A total of 100 patients were enrolled in the study, and a subset of patients was selected as the control group using the propensity score matching method. The results showed that the combination of FSRT and bevacizumab significantly improved IPFS compared to patients treated with FSRT alone or whole-brain radiotherapy (WBRT) plus FSRT. The median IPFS for the combination group was 17.3 months. The median OS and PFS were 26.8 months and 8.4 months, respectively, for the combination group, with no significant differences in OS among the three groups.<br /><br />The treatment-related toxicities of FSRT plus bevacizumab were mild, with low incidence. Reversible mild hypertension and cerebral radio-necrosis occurred in a small number of patients, but there were no signs of extra-lesional hemorrhage or progression of peri-lesional edema.<br /><br />Overall, the combination of FSRT and bevacizumab was well tolerated and achieved promising intracranial disease control in patients with NSCLC. Patients maintained satisfactory QOL after receiving the combined regimen, with a low incidence of cerebral radio-necrosis. These findings suggest that the combination therapy may be a suitable option for the treatment of brain metastases in NSCLC patients.

Asset Subtitle

Rui Zhou

Meta Tag

Speaker Rui Zhou

Topic Metastatic NSCLC: Local Therapies

Keywords

prospective phase II study

bevacizumab

fractionated stereotactic radiotherapy

FSRT

brain metastases

non-small cell lung cancer

intra-cranial disease control

IPFS

toxicities

combination therapy